Investigational Device Exemption (IDE, 21 CFR Part 812): SR vs. NSR, Exempt Studies, and SaMD Trials

An Investigational Device Exemption (IDE) under 21 CFR Part 812 (authorized by Section 520(g) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360j(g)) is the regulatory authorization that permits an unapproved or uncleared medical device—or a cleared/approved device being evaluated for a new intended use involving significant risk—to be shipped in interstate commerce and used in human clinical investigations to collect safety and effectiveness data for an FDA Premarket Approval (PMA), De Novo classification request, or 510(k) premarket notification. Unlike pharmaceutical trials where every clinical study of an unapproved drug requires a single uniform IND path (IND vs. IDE compared), FDA device regulations stratify medical device clinical trials into three risk-based regulatory tiers: IDE-Exempt, Nonsignificant Risk (NSR / Abbreviated IDE), and Significant Risk (SR / Full FDA IDE).

What Are the Three Regulatory Categories of Clinical Device Studies Under 21 CFR Part 812?

Before initiating a human clinical study of a medical device or Software as a Medical Device (SaMD), the sponsor must determine which of the three 21 CFR Part 812 pathways governs the investigation:

Regulatory Tier	CFR Citation	Statutory Definition & Criteria	FDA Submission & IRB Requirements
1. IDE-Exempt Device Study	21 CFR § 812.2(c)	Includes: (1) legally marketed devices used strictly in accordance with cleared/approved labeling (§ 812.2(c)(1)); (2) qualifying non-invasive diagnostic device studies (§ 812.2(c)(3)); (3) consumer preference/modification testing not determining safety/effectiveness (§ 812.2(c)(4))	No IDE submission to FDA; exempt from 21 CFR Part 812 (remains subject to IRB review under 21 CFR Part 56 and informed consent under 21 CFR Part 50 if human subjects are involved)
2. Nonsignificant Risk (NSR) — Abbreviated IDE	21 CFR § 812.2(b)	An investigational device study that is neither IDE-exempt nor meets the definition of a Significant Risk (SR) device	No IDE application submitted to FDA; the IRB serves as the FDA’s surrogate by reviewing the sponsor’s NSR risk determination. Considered to have an approved Abbreviated IDE once the IRB concurs with NSR status and approves the study
3. Significant Risk (SR) — Full FDA IDE	21 CFR § 812.3(m) & § 812.20	A device that: (1) is intended as an implant and presents a potential for serious risk to the health, safety, or welfare of a subject; (2) is purported or represented to be for use in supporting or sustaining human life and presents a potential for serious risk; (3) is for a use of substantial importance in diagnosing, curing, mitigating, or treating disease and presents a potential for serious risk; or (4) otherwise presents a potential for serious risk	Full IDE application to FDA required (21 CFR § 812.20) plus IRB approval. Study may not begin until 30 calendar days after FDA receives the IDE (or earlier upon written FDA approval) and the IRB approves

The Four-Part Test for IDE-Exempt Diagnostic Device Studies (21 CFR § 812.2(c)(3))

For in vitro diagnostics (IVDs), non-invasive wearable physiological sensors, and diagnostic imaging or clinical AI algorithms, 21 CFR § 812.2(c)(3) exempts the study from IDE requirements only if all four statutory conditions are met (and the device is labeled “For Research Use Only” or “For Investigational Use Only” under 21 CFR § 809.10(c)):

1. Non-Invasive Sampling: The testing is non-invasive (defined in § 812.3(k) as not penetrating or piercing the skin or mucous membranes beyond natural body orifices, excluding simple venipuncture or capillary fingerstick blood collection and noninvasive imaging not introducing significant energy).
2. No Invasive Sampling Procedure presenting Significant Risk: Does not require an invasive sampling procedure that presents significant risk (for example, an investigational bronchoalveolar lavage, lumbar puncture, or tissue biopsy performed solely for the study invalidates the exemption).
3. No Energy Introduction by Design or Intention: Does not by design or intention introduce energy into a subject.
4. Not Used as a Diagnostic Procedure Without Confirmation by Another Medically Established Diagnostic Product or Procedure: If clinicians use the unvalidated investigational test or AI output to make real-time patient management decisions (such as initiating therapy, withholding standard-of-care diagnostics, or triaging surgical intervention) without first confirming the result via an FDA-cleared gold-standard test, the study fails prong 4 and requires an NSR or SR IDE.

What Are the Abbreviated IDE Requirements (21 CFR § 812.2(b)) for Nonsignificant Risk (NSR) Studies?

When an IRB agrees that a non-exempt device study poses Nonsignificant Risk (NSR), the sponsor does not file an IDE application with FDA CDRH. Instead, under 21 CFR § 812.2(b)(1), the investigation is deemed to have an approved Abbreviated IDE so long as the sponsor and investigators comply with seven streamlined requirements:

• Investigational Labeling (21 CFR § 812.5): The device must bear the statement: “CAUTION — Investigational device. Limited by Federal (or United States) law to investigational use.”
• IRB Approval and Continuing Review (21 CFR Part 56): Obtain and maintain IRB approval and concurrence with the NSR determination.
• Informed Consent (21 CFR Part 50): Obtain documented informed consent from every subject.
• Monitoring (21 CFR § 812.46): Monitor the investigation and address unanticipated adverse device effects (UADEs).
• Records and Reports (21 CFR § 812.140(b)(4)–(5) & § 812.150(b)(1)–(3), (5)–(10)): Maintain abbreviated sponsor/investigator records; crucially, if an IRB ever determines that a study presented as NSR is actually Significant Risk, the sponsor must notify the FDA within 5 working days (§ 812.150(b)(9)).
• Prohibition on Promotion and Commercialization (21 CFR § 812.7): No commercial promotion, test marketing, or charging more than cost recovery without justification.

How Do IRBs and FDA Make Significant Risk vs. Nonsignificant Risk Determinations for Clinical Decision Support and AI/ML SaMD Trials?

Under the FDA Information Sheet Guidance on Significant Risk and Nonsignificant Risk Medical Device Studies, risk determination evaluates the combined risk of the device AND the clinical study protocol procedures—specifically, the worst-case clinical harm to a trial participant if the algorithm or device outputs a false-positive or false-negative result:

• Silent / Shadow-Mode AI Validation (IDE-Exempt under § 812.2(c)(3)): If an investigational radiology CADt triage algorithm or sepsis prediction model runs silently in the background on EHR or PACS data—where outputs are hidden from treating clinicians and never influence patient care—the study satisfies all four prongs of 21 CFR § 812.2(c)(3) and is IDE-exempt.
• Interventional Adjunctive SaMD with Clinician Confirmation (Typically NSR Abbreviated IDE): If an investigational SaMD displays an advisory score for a non-life-threatening condition where standard-of-care diagnostic confirmation remains mandatory before any treatment change, IRBs frequently classify the trial as NSR (§ 812.2(b)).
• Autonomous or High-Acuity Interventional AI/SaMD (Significant Risk Full IDE): If an investigational algorithm drives closed-loop insulin/vasopressor dosing, triages life-threatening stroke/PE without independent confirmation, or guides invasive surgical ablation where a false negative or false positive could cause death, permanent impairment, or missed critical intervention, the study is Significant Risk (§ 812.3(m)) and requires a 30-day FDA IDE submission. Sponsors uncertain whether a trial is Exempt, NSR, or SR can submit a free Study Risk Determination Q-Submission (Q-Sub) to FDA CDRH for a binding written risk determination.

Finally, once FDA approves a full IDE, CMS assigns the study to Medicare IDE Category A (experimental Class III devices where Medicare covers routine care costs under NCD 310.1 and CMS device coverage pathways, but not the device itself) or Medicare IDE Category B (non-experimental/investigational devices—such as generational iterations of proven device classes—where Medicare covers both routine care costs and the investigational device under 42 CFR § 405.201).

Frequently Asked Questions

What is an Investigational Device Exemption (IDE) under 21 CFR Part 812?

An Investigational Device Exemption (IDE) is the FDA regulatory framework under 21 CFR Part 812 that permits an unapproved or uncleared medical device to be legally shipped and evaluated in human clinical trials to gather safety and effectiveness evidence while exempting the device from premarket clearance/approval and commercial labeling rules.

What are the three regulatory categories of clinical device studies: Exempt (21 CFR § 812.2(c), including non-invasive diagnostic studies under § 812.2(c)(3)), Nonsignificant Risk (NSR Abbreviated IDE under § 812.2(b)), and Significant Risk (SR Full FDA IDE)?

IDE-Exempt studies (§ 812.2(c))—including non-invasive diagnostic studies where results are confirmed by an established diagnostic procedure (§ 812.2(c)(3))—require no IDE submission. Nonsignificant Risk (NSR) studies (§ 812.2(b)) operate under an Abbreviated IDE approved directly by the local IRB without an FDA filing. Significant Risk (SR) studies (§ 812.3(m)) pose a potential for serious risk to subject health or safety and require both IRB approval and a formal 30-day IDE application approved by the FDA before enrollment begins.

How do IRBs and FDA make Significant Risk vs. Nonsignificant Risk determinations for clinical decision support and AI/ML SaMD trials?

IRBs and the FDA evaluate how the software output is used in the clinical protocol and the worst-case clinical consequence of an erroneous algorithm output. Shadow-mode AI studies where clinicians never see the output are typically IDE-exempt under § 812.2(c)(3), whereas prospective trials where an AI/ML SaMD directs high-acuity diagnostic or therapeutic decisions for serious conditions without independent gold-standard confirmation are classified as Significant Risk (SR) requiring a full FDA IDE.